Latest filing published 21 Sept 2026 for C4 Therapeutics, Inc., €8,194. Read the official filing
Kendra Adams (finance chief) discloses dealings in C4 Therapeutics, Inc. to SEC (Form 4). In total, 14 filings cover trades dated from 18 September 2023 to 18 September 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 21 September 2026 came the latest disclosure, a share grant for €8,194 in C4 Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations